An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation
Open Access
- 13 December 2020
- journal article
- research article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 11 (9) , 2694-2708
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Deutsche Forschungsgemeinschaft (CRC1279, MU 3115, MU 3115/11-1)
- Boehringer Ingelheim Stiftung
- Baden-Württemberg Stiftung (EXC 2033–390677874)
This publication has 59 references indexed in Scilit:
- An Antedrug of the CXCL12 Neutraligand Blocks Experimental Allergic Asthma without Systemic Effect in MiceJournal of Biological Chemistry, 2013
- The zebrafish embryo as a tool for screening and characterizing pleurocidin host-defense peptides as anti-cancer agentsDisease Models & Mechanisms, 2011
- Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide AntagonistsScience, 2010
- Innate Cells and T Helper 2 Cell Immunity in Airway InflammationImmunity, 2009
- Structural Basis of CXCR4 Sulfotyrosine Recognition by the Chemokine SDF-1/CXCL12Science Signaling, 2008
- MAPKs and their relevance to arthritis and inflammationRheumatology, 2007
- Role of the SDF-1/CXCR4 Axis in the Pathogenesis of Lung Injury and FibrosisAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitisProceedings of the National Academy of Sciences, 2006
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996